Blueprint Medicines (BPMC) reported $71.96 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 85.6%. EPS of -$1.82 for the same period compares to -$2.65 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $67.28 million, representing a surprise of +6.95%. The company delivered an EPS surprise of +10.78%, with the consensus EPS estimate being -$2.04.
While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.
Here is how Blueprint Medicines performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product revenue, net: $71.03 million versus $64.97 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +136.3% change.
- Revenues- Collaboration and License Revenue: $0.92 million versus $3 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -89.4% change.
- Revenues- Product revenue, net- AYVAKIT/AYVAKYT: $71.03 million compared to the $64.58 million average estimate based on seven analysts. The reported number represents a change of +136.3% year over year.
View all Key Company Metrics for Blueprint Medicines here>>>
Shares of Blueprint Medicines have returned +9.9% over the past month versus the Zacks S&P 500 composite’s +5.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention.
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.